<DOC>
	<DOCNO>NCT00102687</DOCNO>
	<brief_summary>The purpose study determine azacitidine , combine Best Supportive Care ( BSC ) , effective treat myelodysplastic syndrome ( MDS ) give accord different dos dose schedule .</brief_summary>
	<brief_title>Alternative Dosing Regimens Subcutaneous Azacitidine Myelodysplastic Syndromes</brief_title>
	<detailed_description>Comparison/Control Interventions : The comparison azacitidine different dos schedule . Duration Intervention : Treatment last maximum 18 cycle , 24 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis refractory anemia , refractory anemia ring sideroblast least one following : ) Anemia hemoglobin &lt; 110g/L require least 1 unit pack red blood cell transfusion every 28 day ; b ) Thrombocytopenia platelet count &lt; 100 x 10^9/L ; c ) Neutropenia absolute neutrophil count &lt; 1.5 x 10^9/L . OR , Refractory anemia excess blast refractory anemia excess blast transformation , accord FrenchAmericanBritish classification system MDS . At least 18 year age . Have life expectancy &gt; 7 month . Unlikely proceed bone marrow stem cell transplantation therapy follow remission . Have serum bilirubin level less equal 1.5 time upper limit normal ( ULN ) range laboratory . Have serum glutamicoxaloacetic transaminase ( aspartate aminotransferase ) serum glutamicpyruvic transaminase ( alanine aminotransferase ) level less equal 2 x ULN . Have serum creatinine level less equal 1.5 x ULN . Secondary MDS . Prior treatment azacitidine . Any prior history Acute Myeloid Leukemia ( AML ) . Malignant metastatic disease within previous 12 month . Uncorrected red cell folate deficiency vitamin B12 deficiency . Hepatic tumor . Radiation , chemotherapy , cytotoxic therapy nonMDS condition previous 12 month . Known suspect hypersensitivity azacitidine mannitol . Prior transplantation cytotoxic therapy treat MDS . Prior use Revlimid Thalomid allow 30 day washout . Serious medical illness likely limit survival less equal 7 month . Treatment androgenic hormone previous 14 day Active viral infection know human immunodeficiency virus vial hepatitis Type B C. Treatment investigational drug previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>